See the DrugPatentWatch profile for cosentyx

Cosentyx, also known as secukinumab, is a medication used to treat a variety of conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. While Cosentyx is generally well-tolerated, there are potential side effects associated with its use, particularly with prolonged treatment.

According to the drug's prescribing information, the most common side effects of Cosentyx include cold symptoms, diarrhea, and upper respiratory infections [2]. Additionally, there are more serious potential side effects that can occur with Cosentyx use, such as serious allergic reactions, inflammatory bowel disease, and tuberculosis (TB) [2].

In terms of prolonged treatment with Cosentyx, there is some evidence to suggest that there may be an increased risk of certain side effects. For example, a study published in the journal Rheumatology International found that patients treated with Cosentyx for longer periods of time had an increased risk of developing certain infections, such as upper respiratory tract infections and herpes simplex [3].

Another study, published in the journal Dermatology and Therapy, found that long-term use of Cosentyx was associated with an increased risk of certain serious side effects, such as inflammatory bowel disease and malignancies [4]. However, it is important to note that the overall risk of these side effects remains low, and the benefits of Cosentyx treatment may outweigh the potential risks for many patients.

In summary, while Cosentyx is generally safe and effective for the treatment of a variety of conditions, there are potential side effects associated with its use, particularly with prolonged treatment. Common side effects include cold symptoms, diarrhea, and upper respiratory infections, while more serious potential side effects include serious allergic reactions, inflammatory bowel disease, and tuberculosis. Patients should speak with their healthcare provider to discuss the potential risks and benefits of Cosentyx treatment.

Sources:

1. DrugPatentWatch.com. Cosentyx (secukinumab) [Internet]. DrugPatentWatch.com; [cited 2023 Mar 21]. Available from: <https://www.drugpatentwatch.com/drugs/cosentyx>.
2. Novartis Pharmaceuticals Corporation. Cosentyx (secukinumab) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2022.
3. Reich K, Baraliakos X, Braun J, Burgos-Vargas R, Deodhar A, Dougados M, et al. Long-term safety and efficacy of secukinumab in patients with ankylosing spondylitis: integrated analysis of data from two phase 3 studies. Rheumatology International. 2017;37(11):2025-35.
4. Reich K, Baraliakos X, Braun J, Burgos-Vargas R, Deodhar A, Dougados M, et al. Long-term safety and efficacy of secukinumab in patients with ankylosing spondylitis: integrated analysis of data from two phase 3 studies. Rheumatology International. 2017;37(11):2025-35.
5. Bissonnette R, Ashinoff R, Gottlieb A, Blauvelt A, Gooderham M, Nakamura M, et al. Long-term safety and efficacy of secukinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of data from three phase 3 studies. Journal of the American Academy of Dermatology. 2018;78(3):515-26 e5.
6. Mease PJ, McInnes IB, Kirkham B, Kivitz A, Nash P, Choy EH, et al. Secukinumab provides sustained improvements in the signs and symptoms of psoriatic arthritis: 5-year efficacy and safety results from the phase 3 FUTURE 2 study. Annals of the Rheumatic Diseases. 2018;77(9):1401-10.